Gene · 974
Papers4,161
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
521 to 540 of 4,161
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Analyzation of the Peripheral Blood Mononuclear Cells Atlas and Cell Communication of Rheumatoid Arthritis Patients Based on Single-Cell RNA-Seq. | J Immunol Res | 2023 | 37600067 | PubTator, text mining | PubMed |
| Genomic properties and clinical outcomes associated with tertiary lymphoid structures in patients with breast cancer. | Sci Rep | 2023 | 37598257 | PubTator, text mining | PubMed |
| The oncogenic human B-cell lymphoma MYD88 L265P mutation genocopies activation by phosphorylation at the Toll/interleukin-1 receptor (TIR) domain. | Blood Cancer J | 2023 | 37591861 | PubTator, text mining | PubMed |
| Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. | Signal Transduct Target Ther | 2023 | 37591844 | PubTator, text mining | PubMed |
| Circulating IRF8-expressing CD123+CD127+ lymphoid progenitors: key players in human hematopoiesis. | Trends Immunol | 2023 | 37591714 | PubTator, text mining | PubMed |
| Yolk sac cell atlas reveals multiorgan functions during human early development. | Science | 2023 | 37590359 | PubTator, text mining | PubMed |
| B-cell prolymphocytic leukemia with P53 abnormalities successfully treated with bendamustine and rituximab: a report of three cases. | Transl Cancer Res | 2023 | 37588745 | PubTator, text mining | PubMed |
| Human granzyme B regulatory B cells prevent effector CD4+CD25- T cell proliferation through a mechanism dependent from lymphotoxin alpha. | Front Immunol | 2023 | 37588598 | PubTator, text mining | PubMed |
| Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study. | Blood Adv | 2023 | 37581593 | PubTator, text mining | PubMed |
| The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma. | Exp Hematol Oncol | 2023 | 37580826 | PubTator, text mining | PubMed |
| Identification of stromal cell proportion-related genes in the breast cancer tumor microenvironment using CorDelSFS feature selection: implications for tumor progression and prognosis. | Front Genet | 2023 | 37576555 | PubTator, text mining | PubMed |
| The role of N-glycosylation in B-cell biology and IgG activity. The aspects of autoimmunity and anti-inflammatory therapy. | Front Immunol | 2023 | 37575234 | PubTator, text mining | PubMed |
| Antibody-Drug Conjugates: A Review of Approved Drugs and Their Clinical Level of Evidence. | Cancers (Basel) | 2023 | 37568702 | PubTator, text mining | PubMed |
| Interleukin 4-driven reversal of self-reactive B cell anergy contributes to the pathogenesis of systemic lupus erythematosus. | Ann Rheum Dis | 2023 | 37567607 | PubTator, text mining | PubMed |
| Outcome prediction by interim positron emission tomography and IgM monoclonal gammopathy in diffuse large B-cell lymphoma. | Ann Hematol | 2023 | 37566280 | PubTator, text mining | PubMed |
| The clinical and molecular taxonomy of t(14;18)-negative follicular lymphomas. | Blood Adv | 2023 | 37561599 | PubTator, text mining | PubMed |
Emerging entities: high-grade/large B-cell lymphoma with 11q aberration, large B-cell lymphoma with IRF4 rearrangement, and new molecular subgroups in large B-cell lymphomas. A report of the 2022 EA4HP/SH lymphoma workshop. | Virchows Arch | 2023 | 37555980 | PubTator, text mining | PubMed |
| Transcriptomic comparison of bone marrow CD34 + cells and peripheral blood neutrophils from ET patients with JAK2 or CALR mutations. | BMC Genom Data | 2023 | 37550636 | PubTator, text mining | PubMed |
| Proteomic analysis of 92 circulating proteins and their effects in cardiometabolic diseases. | Clin Proteomics | 2023 | 37550624 | PubTator, text mining | PubMed |
| [Clinical characteristics of 11 patients with chronic lymphocytic leukemia with t (14;19) (q32;q13)]. | Zhonghua Xue Ye Xue Za Zhi | 2023 | 37550193 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/974/papers?page=27